


Supplementary Figure 9



Supplementary Figure 9: Characterisation of vedolizumab-“resistant” $\beta 1^{+}PI16^{+}\alpha 4^{+}\beta 7^{+}$ T_{Reg} cells in the peripheral blood of IBD patients

(A,B) Quantitative flow cytometry showing mean fluorescence intensity (MFI) of CD25 (A) and Foxp3 (B) on $\beta 1^{+}PI16^{+}\alpha 4^{+}\beta 7^{+}$ T_{Reg} compared with $\beta 1^{-}PI16^{-}\alpha 4^{+}\beta 7^{+}$ T_{Reg} cells. n = 11 IBD patients.

(C) Quantitative flow cytometry showing the frequency of CTLA4-expressing $\beta 1^{+}PI16^{+}\alpha 4^{+}\beta 7^{+}$ T_{Reg} compared with $\beta 1^{-}PI16^{-}\alpha 4^{+}\beta 7^{+}$ T_{Reg} cells. n = 11 IBD patients.

(D) Quantitative flow cytometry showing the frequency and mean fluorescence intensity (MFI) of IL10 on $\beta 1^{+}PI16^{+}\alpha 4^{+}\beta 7^{+}$ T_{Reg} compared with $\beta 1^{-}PI16^{-}\alpha 4^{+}\beta 7^{+}$ T_{Reg} cells after incubation with PMA, ionomycin and brefeldin A for 4 h. n = 11 IBD patients.

(E,F) Quantitative flow cytometry showing mean fluorescence intensity (MFI) of Helios (E) and GITR (F) on $\beta 1^{+}PI16^{+}\alpha 4^{+}\beta 7^{+}$ T_{Reg} compared with $\beta 1^{-}PI16^{-}\alpha 4^{+}\beta 7^{+}$ T_{Reg} cells. n = 11 IBD patients.

Statistical comparisons were performed using paired t-test.

Sample donor characteristics are listed in *Supplementary Table S15*.